Kalaris Therapeutics board director resigns, new director elected

Kalaris Therapeutics, Inc. reported in an 8-K filing signed and dated July 6, 2026, that on July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified the company of her decision to resign as a member of the board of directors, effective immediately.¹ With the resignation, Dr. Jovan-Embiricos also resigned as a member of the Audit Committee of the Board.¹ The company stated her resignation was not related to any disagreement on any matter relating to its operations, policies or practices.¹

Also on July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.¹ Keating will serve as a Class I director with a term expiring at the 2027 annual meeting of stockholders.¹ The Board also elected Keating to serve as a member of the Audit Committee, effective as of August 1, 2026.¹

The filing noted there are no arrangements or understandings between Keating and any other persons pursuant to which she was elected, she has no family relationships with any directors or executive officers, and there are no transactions requiring disclosure under Item 404(a) of Regulation S-K.¹

Under Kalaris's non-employee director compensation policy, Keating will be granted an option to purchase 18,000 shares of common stock at fair market value on the August 1, 2026 grant date, vesting in equal monthly installments over three years.¹ Vesting would accelerate in full upon a change in control.¹ She will also receive $40,000 in annual cash compensation as a board member and an additional $7,500 for Audit Committee service, plus annual equity grants and expense reimbursement.¹